Adverse event episodes that occurred in more than one patient and were attributed as being possibly, probably, or definitely related to drug in patients with MMM treated with lenalidomide at either Mayo Clinic (10 mg/day; n = 27) or M. D. Anderson Cancer Center (MDACC; n = 41; 10 mg or 5 mg/day)
. | No. patients (%) . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
. | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | All grades . | ||||
| Neutropenia | |||||||||
| Mayo Clinic | 1 (4) | 6 (22) | 7 (23) | 1 (4) | 15 (56) | ||||
| MDACC | 0 | 0 | 4 (10) | 9 (22) | 13 (32) | ||||
| Fatigue | |||||||||
| Mayo Clinic | 2 (7) | 8 (30) | 2 (7) | 2 (7) | 14 (52) | ||||
| MDACC | 0 | 0 | 3 (7) | 0 | 3 (7) | ||||
| Thrombocytopenia | |||||||||
| Mayo Clinic | 5 (19) | 3 (11) | 2 (7) | 0 | 10 (37) | ||||
| MDACC | 0 | 0 | 4 (10) | 7 (17) | 11 (27) | ||||
| Pruritis | |||||||||
| Mayo Clinic | 8 (30) | 2 (7) | 0 | 0 | 10 (37) | ||||
| MDACC | 8 (20) | 0 | 1 (2) | 0 | 9 (22) | ||||
| Anemia | |||||||||
| Mayo Clinic | 0 | 4 (15) | 2 (7) | 1 (4) | 7 (26) | ||||
| MDACC | 0 | 0 | 0 | 0 | 0 | ||||
| Dyspnea/hypoxia | |||||||||
| Mayo Clinic | 0 | 1 (4) | 4 (15) | 0 | 5 (19) | ||||
| MDACC | 0 | 0 | 0 | 0 | 0 | ||||
| Rash | |||||||||
| Mayo Clinic | 0 | 1 (4) | 1 (4) | 1 (4) | 3 (11) | ||||
| MDACC | 8 (20) | 6 (15) | 2 (5) | 0 | 16 (39) | ||||
. | No. patients (%) . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|
. | Grade 1 . | Grade 2 . | Grade 3 . | Grade 4 . | All grades . | ||||
| Neutropenia | |||||||||
| Mayo Clinic | 1 (4) | 6 (22) | 7 (23) | 1 (4) | 15 (56) | ||||
| MDACC | 0 | 0 | 4 (10) | 9 (22) | 13 (32) | ||||
| Fatigue | |||||||||
| Mayo Clinic | 2 (7) | 8 (30) | 2 (7) | 2 (7) | 14 (52) | ||||
| MDACC | 0 | 0 | 3 (7) | 0 | 3 (7) | ||||
| Thrombocytopenia | |||||||||
| Mayo Clinic | 5 (19) | 3 (11) | 2 (7) | 0 | 10 (37) | ||||
| MDACC | 0 | 0 | 4 (10) | 7 (17) | 11 (27) | ||||
| Pruritis | |||||||||
| Mayo Clinic | 8 (30) | 2 (7) | 0 | 0 | 10 (37) | ||||
| MDACC | 8 (20) | 0 | 1 (2) | 0 | 9 (22) | ||||
| Anemia | |||||||||
| Mayo Clinic | 0 | 4 (15) | 2 (7) | 1 (4) | 7 (26) | ||||
| MDACC | 0 | 0 | 0 | 0 | 0 | ||||
| Dyspnea/hypoxia | |||||||||
| Mayo Clinic | 0 | 1 (4) | 4 (15) | 0 | 5 (19) | ||||
| MDACC | 0 | 0 | 0 | 0 | 0 | ||||
| Rash | |||||||||
| Mayo Clinic | 0 | 1 (4) | 1 (4) | 1 (4) | 3 (11) | ||||
| MDACC | 8 (20) | 6 (15) | 2 (5) | 0 | 16 (39) | ||||
Toxicity grades are according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.